Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic


Pemigatinib Trial Seeks to Build on Targeted Advances in Cholangiocarcinoma

September 22, 2020

An explosion of research in the field led to the approval of pemigatinib in April 2020 for patients with unresectable, previously treated advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.